^
    Back
    Association details:
    Biomarker:BIRC3 mutation
    Cancer:Chronic Lymphocytic Leukemia
    Regimen: (cyclophosphamide + fludarabine IV + Rituxan (rituximab))
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EHA 2018
    Title:

    GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE

    Published date:
    05/17/2018
    Excerpt:
    To analyze progression-free survival (PFS) according to the presence of genetic defects in CLL patients treated with front line FCR or BR regimen...trend to shorter PFS in patients with BIRC3 mutations (19 vs. 28 m in BIRC3-wt patients; P = 0.056).